Safety of Treatment

With so little known about COVID-19 it is hard to be definitive about any of the risks associated with it, however, we have no evidence that it is being transmitted through blood or blood products.  Haemophilia Scotland will gather the latest thinking on blood product safety and publish it here.

The Plasma Protein Therapeutics Association (PPTA) has issued a statement stating that the “2019-nCoV is not a concern for the safety of plasma protein therapies manufactured by PPTA member companies” at this time. The association stated that “existing manufacturing methods provide significant safety margins against the 2019-nCoV.”

The European Haemophilia Consortium (EHC) is also monitoring the situation and referring concerned individuals to the European Centre for Disease Prevention and Control (ECDC), which has been following developments of the outbreak.

World Federation of Hemophilia (WFH) has also issued a statement on the coronavirus for people who may have concerns about travel to their 2020 World Congress in Kuala Lumpur, Malaysia.

Haemophilia Scotland is contacting all the manufacturers of clotting products, prioritising those who produce plasma-derived products, and we will update these pages with any information they provide us.

Last updated: 20 March 2020

Briefings from Pharmaceutical Companies